NEW YORK – Create Medicines has started clinically testing an in vivo CAR therapy that comprises a cancer-killing medley of T, NK, and myeloid cells.

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example | Despite the recent “feeding ...

Chimeric antigen receptor T-cell therapy conferred sustained benefit to individuals with high-risk smoldering multiple myeloma, according to phase 2 trial results. All patients who received a single ...

A clinical trial to reverse age-related vision conditions using stem cell treatment could finally deliver on the promise of a ...

A personalized CAR T-cell therapy has sent a patient with three life-threatening autoimmune diseases into remission for over a year, after conventional treatments failed. The case adds to mounting ...

Researchers are advancing in vivo CAR-T cell engineering, which generates therapeutic immune cells directly inside patients, bypassing complex lab manufacturing. This approach could broaden access, ...

At AACR 2026, prominent cancer researchers discussed the latest advances in mitigating tumor evasion, targeting cancer ...

A "beautiful" nurse who passed away just 13 days after doctors found a cancerous brain tumour told her eldest daughter on the ...

In 2013, Jeannie was diagnosed with Non-Hodgkin lymphoma and she underwent multiple rounds of chemotherapy, reaching ...

Medically integrated dispensing improves affordability, adherence, and toxicity management via embedded pharmacy teams, ...